$MRK News

Morgan Stanley Upgrades Merck (MRK)

RBC Capital Downgrades Merck (MRK)

BMO Capital Maintains Outperform on Merck & Co, Raises Price Target to $170

UBS Maintains Buy on Merck & Co, Raises Price Target to $175

RBC Capital Downgrades Merck & Co to Sector Perform, Raises Price Target to $150

Merck And Moderna's Melanoma Results

Morgan Stanley Upgrades Merck & Co to Overweight, Raises Price Target to $179

Bernstein's Courtney Breen talks the massive rally in Moderna stock

Merck Soars On Cancer Vaccine Trial Win With Moderna, More Upside Ahead

Merck: Why Consolidation Looks Like The Next Move (Rating Downgrade)

Moderna's Cancer Vaccine Win Is Merck's Story Too

Moderna Stock Jumps 150%, Best Day Ever On Cancer Vaccine Win

Moderna stock nearly doubles on new cancer vaccine results

'An increased ability to be disease-free': Moderna CEO & Merck's Dr. Li on skin cancer vaccine trial

Merck and Moderna Release Landmark Personalized Cancer Therapy Trial Success, Stocks Soar

Merck And Moderna Announce Topline Results From The Phase 3 Interpath-001 Trial Evaluating Adjuvant Treatment With Intismeran Autogene In Combination With KEYTRUDA In Patients With Completely Resected Stage IIB-IV Melanoma; At A Pre-specified Interim Analysis, Intismeran In Combination With KEYTRUDA As Adjuvant Therapy Demonstrated Statistically Significant And Clinically Meaningful Improvements In RFS And DMFS Compared To KEYTRUDA Alone

Jennifer Zachary At Merck & Co Capitalizes: Options Exercised, Resulting In $1.33M

Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine

Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress

Merck (MRK) Stock Looks Fully Valued Following Raised Revenue Outlook